On June 19, 2020, Glenmark became the first company in India to receive restricted emergency use approval from India's drug regulator for Favipiravir (FabiFlu).
Glenmark Life Sciences IPO Listing Date, Glenmark Life Sciences Share Price: Glenmark Life Sciences IPO GMP is currently at Rs 85.
Glenmark Life Sciences IPO Allotment status, Glenmark IPO GMP today: Glenmark Life Sciences IPO allotment status has been finalised. Glenmark IPO allotment status is available on KFintech's website. Glenmark Life Sciences shares will be listed on the BSE and NSE on August 6.
Glenmark Life Sciences IPO Allotment, Glenmark Life Sciences IPO GMP Latest: Glenmark Life Sciences IPO allotment status will be available on the website of KFintech.
Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.
Glenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19.
Shares of Glenmark Pharmaceuticals on Monday tumbled nearly 6 per cent after India's drug regulator sought clarification from the company over its alleged "false claims" about the use of anti-viral FabiFlu on COVID-19 patients with comorbidities and also over the "pricing" of the drug.
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
Glenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to moderate COVID-19.
Shares of Glenmark Pharmaceuticals on Monday rallied 20 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Glenmark Coronavirus medicine FabiFlu launched at Rs 103 per tablet: Glenmark's FabiFlu has been approved for coronavirus treatment in India. FabiFlu is the first oral Favipiravir-approved medication in India for the treatment of COVID-19, the company said in a statement.
Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients, after it received the Indian drug regulator Drug Controller General of India (DCGI) approval.
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.
Shares of the drug firm fell to its 52-week low level of Rs 284.40, on the BSE, registering a decline of 9.90 per cent over its previous closing price.
Glenmark Pharmaceuticals has been granted a final approval from the US Food and Drug Administration (USFDA) for sale of Tretinoin Capsules, used in treatment of leukemia. "Glenmark Pharmaceuticals Inc., USA has been granted final approval
New Delhi: The Delhi High Court today restrained Indian firm Glenmark Pharmaceuticals from manufacturing, marketing or selling its anti-diabetes drugs Zita and Zita-Met, saying it has "prima facie" infringed the patent of US drug major
Top News
Latest News
